Patricia Schirmer1, Mark Holodniy. 1. Stanford University, VA Palo Alto Health Care System, Division of Infectious Diseases & Geographic Medicine, Palo Alto, CA 94304, USA. mark.holodniy@va.gov
Abstract
BACKGROUND: Influenza infection is a global problem affecting millions of people worldwide, despite efficacious vaccines. Treatment and prophylaxis against influenza have been successful using antiviral medications such as adamantanes and neuraminidase inhibitors. OBJECTIVE: To review the antiviral agents and specifically the neuraminidase inhibitor, oseltamivir, for use in treatment and prophylaxis of influenza infection. METHODS: This review focuses on published literature regarding the clinical use of oseltamivir, as well as discussing emerging threats such as avian influenza, antiviral resistance, and strategies such as combination antiviral treatment to mitigate these threats. RESULTS: Oseltamivir is effective in reducing symptom burden in those with influenza A or B infection, and is preventative against developing infection after exposure. Emergence of naturally occurring or post-treatment oseltamivir-resistant influenza as well as an avian influenza pandemic may limit its future use as a monotherapeutic antiviral treatment agent.
BACKGROUND:Influenza infection is a global problem affecting millions of people worldwide, despite efficacious vaccines. Treatment and prophylaxis against influenza have been successful using antiviral medications such as adamantanes and neuraminidase inhibitors. OBJECTIVE: To review the antiviral agents and specifically the neuraminidase inhibitor, oseltamivir, for use in treatment and prophylaxis of influenza infection. METHODS: This review focuses on published literature regarding the clinical use of oseltamivir, as well as discussing emerging threats such as avian influenza, antiviral resistance, and strategies such as combination antiviral treatment to mitigate these threats. RESULTS:Oseltamivir is effective in reducing symptom burden in those with influenza A or B infection, and is preventative against developing infection after exposure. Emergence of naturally occurring or post-treatment oseltamivir-resistant influenza as well as an avian influenza pandemic may limit its future use as a monotherapeutic antiviral treatment agent.
Authors: Margaret Okomo-Adhiambo; Gail J Demmler-Harrison; Varough M Deyde; Tiffany G Sheu; Xiyan Xu; Alexander I Klimov; Larisa V Gubareva Journal: Antimicrob Agents Chemother Date: 2010-03-01 Impact factor: 5.191
Authors: Philippe Simon; Benjamin P Holder; Xavier Bouhy; Yacine Abed; Catherine A A Beauchemin; Guy Boivin Journal: J Clin Microbiol Date: 2010-11-24 Impact factor: 5.948
Authors: Bhavna Bhasin; Vineet Veitla; Aprill Z Dawson; Zhuping Garacci; Daniel Sturgill; Mukoso N Ozieh; Kevin R Regner Journal: Kidney360 Date: 2021-02-26